Clinical trial
Chemoradiation Versus Chemotherapy in Combination with Tislelizumab As First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 Trial
NCT05919030 is registered in ClinicalTrials.gov with Renmin Hospital of Wuhan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Chemoradiation Versus Chemotherapy in Combination with Tislelizumab As First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 Trial
- Lead sponsor
- Renmin Hospital of Wuhan University
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 1, 2023
- Completion date
- July 1, 2027
- Enrollment
- 155 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.